No Data
No Data
Regeneron Pharma Is Maintained at Overweight by Piper Sandler
Regeneron Pharmaceuticals Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?
Express News | Regeneron Pharmaceuticals Inc : Piper Sandler Raises Target Price to $1242 From $1166
In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge
No Data
104656319 : hy
webguybob : so how do we use moo to identify potential high performance stocks in the broader sectors?
73279472 : ok
71768068 webguybob : simply russell2000
webguybob 71768068 : I recently shifted most of my large caps to ishares IWF, so I might be covered?
View more comments...